Registry cohort study reveals worse survival and distinct risk profiles in triple-negative breast cancer, highlighting the need for tailored therapeutic strategies.
Triple-negative tumors were associated with unique risk factors and worse outcomes compared with HR-positive/HER2-negative tumors.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: